Fundraising FoxAtlas Venture — 2025 Investments
7 investments dated 2025 · listed companies and verified rows first · show all
Antares Therapeutics discovers and develops precision medicines, with a focus on small molecule therapies targeting previously undruggable oncology targets and other serious diseases.
AI & Machine LearningBiotechMedical DevicesCambridge, US
Adam Friedman(Chief Executive Officer)inAndrew Fedder(Executive Officer, Director)inBrian Piper(Executive Officer, Director)in
Board seatJean-François Formela· per SEC Form D
Co-investorsLightspeed Venture PartnersVida VenturesOmega FundsTenmileAbingworthAlleyCorp+1 more
TRIANA Biomedicines is a venture-backed biopharmaceutical company developing small-molecule "molecular glue" therapeutics that induce protein:protein interactions to degrade or alter disease-causing target proteins, with an initial focus on targeted protein degradation for cancer.
BiotechDeep TechHealthtechLexington, US
Patrick Trojer(President & Chief Executive Officer)in
Board seatDavid Grayzel· per SEC Form D
Co-investorsAscenta CapitalLightspeed Venture PartnersRA CapitalBessemer Venture PartnersPfizer VenturesFinchley Healthcare Ventures+3 more
Lifordi Immunotherapeutics develops treatments for immunology and rare diseases through discovery, clinical development, and commercialization.
BiotechDeep TechHealthtechBurlington, MA, US
Jay Rothstein, Ph.D.(Scientific Co-Founder and Advisor)Arthur O. Tzianabos, Ph.D.(President and CEO)Naina Bhasin, Ph.D.(Chief Business Officer)Arthur Tzianabos, Ph.D.(President & Chief Executive Officer)
Co-investorsARCH Venture PartnersSanofi Ventures5AM Ventures
Vima Therapeutics is a biotech company developing drug treatments for movement disorders such as dystonia and related neurological diseases.
BiotechHealthtechMedical Devices
Bernard Ravina(Founder and Chief Executive Officer)inJudy Dunn(President of Research & Development)Jessica Fees(Chief Financial Officer)inAriel D. Jasie(Chief Business Officer and General Counsel)inTushar Misra(Chief Technical Officer)in
Co-investorsFrazier Life SciencesAccess IndustriesAccess BiotechnologyCanaan Partners
Affinia Therapeutics develops genetically engineered adeno-associated virus (AAV) therapies for treating genetic diseases, focusing initially on cardiovascular and central nervous system conditions.
AI & Machine LearningBiotechDeep TechWaltham, US
Luc Vandenberghe(Director)Aaron Tward, M.D., Ph.D.(Scientific Co-Founder)Botond Roska, M.D., Ph.D.(Scientific Co-Founder)Luk Vandenberghe, Ph.D.(Scientific Co-Founder and Adviser, and Board Member)Rami Daoud(Executive Officer)inRick Modi(Chief Executive Officer, Board Member)
Board seatDavid Grayzel· per SEC Form D
Co-investorsEcoR1 CapitalEight Roads VenturesF-Prime CapitalGV (Google Ventures)New Enterprise Associates (NEA)TCG Crossover
Renasant Bio is a biopharmaceutical company developing oral small molecule corrector and potentiator therapies to restore the function of polycystin 1 and 2 proteins in autosomal dominant polycystic kidney disease (ADPKD).
BiotechHealthtechBerkeley, US
Jeremy Reiter(Scientific Co-Founder)Markus Delling(Scientific Co-Founder)Thomas Gustafson(Executive Officer)inEmily Conley(Executive Officer, Director)in
BoardEvan Caplan(Director)inCharlotte McKee(Director)
Board seatKevin Bitterman· per SEC Form D
Co-investors5AM VenturesOrbiMedQiming Venture PartnersQiming Venture Partners USA
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.